The Pfizer mRNA Vaccine: Pharmacokinetics and Toxicity

The dangers of the COVID-19 vaccine spike protein and its interactions with the human immune system, conferring risks of clotting and leakage of blood vessels, are becoming increasingly well known. But how far and wide in the body can such dangers spread? What does that mean for vaccine safety?

And what of the vaccine lipid nanoparticle (LNP), composed of lipids that have never been injected into human beings before?

What does the existing evidence on vaccine pharmacokinetics, and the toxicity of its components, reveal? Why can the vaccines be expected to cause:

blood clotting shortly after vaccination, potentially leading to heart attacks, stroke, and venous thrombosis
grave harm to female fertility
grave harm to breastfed infants
cumulative toxicity after multiple injections?

In this detailed analysis, Associate Professor Michael Palmer and Professor Sucharit Bhakdi explain. They write:

We summarize the findings of an animal study which Pfizer submitted to the Japanese health authorities in 2020, and which pertained to the distribution and elimination of a model mRNA vaccine. We show that this study clearly presaged grave risks of blood clotting and other adverse effects. The failure to monitor and assess these risks in the subsequent clinical trials, and the grossly negligent review process in conjunction with the emergency use authorizations, have predictably resulted in an unprecedented medical disaster.

Of particularly grave concern is the very slow elimination of the toxic cationic lipids. In persons repeatedly injected with mRNA vaccines containing these lipids— be they directed against COVID, or any other pathogen or disease—this would result in cumulative toxicity. There is a real possibility that cationic lipids will accumulate in the ovaries. The implied grave risk to female fertility demands the most urgent attention of the public and of the health authorities.